#reports #VERO
[Venus Concept](https://eninvs.com/company%5fUS%5fwide.php?name=VERO) (Medical Devices) reported for 2022 q2
(2022-08-12, Before Market Open):
- Revenue -3.8% YoY (vs +13.0% in previous quarter and historical rate +70.6%)
- EBITDA -400.0% YoY (vs -700.0% in previous quarter)
- EBITDA margin -36.0% decreased compared to 11.5% same period last year
- Net Debt increased by $7.0 mln over the past reporting period (19.0% of market cap)
- FCF (LTM) -$0.0 bln (negative), 32.6% of market cap
- EV/Sales multiple is 1.0x
The company showed EPS -$0.16 per share vs analyst consensus of -$0.07. At the opening of the session the share price went down -13.0% vs S&P500 +0.4%
------------------------------------------------
#reports #RYAN
[Ryan Specialty Holdings, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=RYAN) (Insurance — Specialty) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue +25.9% YoY (vs +24.4% in previous quarter and historical rate +25.2%)
- Net Income +39.7% YoY (vs +5100.0% in previous quarter and historical rate +119.8%)
- Net Income margin 17.9% increased compared to 16.2% same period last year
- P/E multiple is 48.6x compared to historical level (75th percentile) of 52.9x
- P/S multiple is 7.3x
- Price to book: 31.6x
The company showed EPS +$0.39 per share vs analyst consensus of +$0.35. At the opening of the session the share price went down -1.4% vs S&P500 +0.4%
------------------------------------------------
#reports #RPID
[Rapid Micro Biosystems, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=RPID) (Medical Devices) reported for 2022 q2
(2022-08-12, Before Market Open):
- Revenue -33.3% YoY (vs -20.0% in previous quarter and historical rate -26.7%)
- Net Debt increased by $13.0 mln over the past reporting period (7.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 11.8% of market cap
- EV/Sales multiple is 6.8x
The company showed EPS -$0.31 per share. At the opening of the session the share price went down -4.5% vs S&P500 +0.4%
------------------------------------------------
#reports #NUZE
[NuZee](https://eninvs.com/company%5fUS%5fwide.php?name=NUZE) (Packaged Foods) reported for 2022 q2
(2022-05-12):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +41.7%)
- EBITDA margin -200.0% increased compared to -300.0% same period last year
- EV/Sales multiple is 2.8x
The company showed EPS -$0.14 per share
------------------------------------------------
#reports #MTEX
[Mannatech](https://eninvs.com/company%5fUS%5fwide.php?name=MTEX) (Household and Personal Products) reported for 2022 q2
(2022-08-10, Before Market Open):
- Revenue -18.6% YoY (vs -15.8% in previous quarter and historical rate +4.9%)
- EBITDA -66.7% YoY (vs -100.0% in previous quarter and historical rate +27.8%)
- EBITDA margin 2.9% decreased compared to 7.0% same period last year
- Net Debt decreased by $4.0 mln over the past reporting period (10.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 10.0% of market cap
- EV/EBITDA multiple is 1.2x compared to historical level (75th percentile) of 3.9x
- EV/Sales multiple is 0.1x
The company showed EPS +$0.34 per share. At the opening of the session the share price went down -4.2% vs S&P500 +1.4%
------------------------------------------------
#reports #MDIA
[MediaCo](https://eninvs.com/company%5fUS%5fwide.php?name=MDIA) (Broadcasting) reported for 2022 q2
(2022-05-12):
- Revenue +60.0% YoY (vs +9.1% in previous quarter and historical rate +55.3%)
- Net Debt increased by $1.0 mln over the past reporting period (3.1% of market cap)
- FCF (LTM) +$0.0 bln (positive), 3.1% of market cap
- EV/EBITDA multiple is 18.1x compared to historical level (75th percentile) of 23.9x
- EV/Sales multiple is 2.4x
The company showed EPS -$0.47 per share
------------------------------------------------
#reports #HNVR
[Hanover Bancorp, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=HNVR) (Banks — Regional) reported for 2022 q2
(2022-06-01):
- Revenue +45.5% YoY (vs +112.5% in previous quarter and historical rate +79.0%)
- P/E multiple is 0.3x compared to historical level (75th percentile) of 5.0x
- P/S multiple is 2.2x
- Price to book: 0.9x
The company showed EPS +$2.06 per share
------------------------------------------------
#reports #HNST
[The Honest Company, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=HNST) (Specialty Retail) reported for 2022 q2
(2022-08-12, Before Market Open):
- Revenue +4.0% YoY (vs -14.8% in previous quarter and historical rate -2.8%)
- EBITDA margin -11.5% increased compared to -25.3% same period last year
- Net Debt decreased by $5.0 mln over the past reporting period (1.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 8.8% of market cap
- EV/Sales multiple is 1.1x
The company showed EPS -$0.11 per share vs analyst consensus of -$0.08. At the opening of the session the share price went down -3.1% vs S&P500 +0.4%
------------------------------------------------
#reports #GRNQ
[Greenpro Capital](https://eninvs.com/company%5fUS%5fwide.php?name=GRNQ) (Consulting Services) reported for 2022 q2
(2022-05-10):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +20.8%)
- EBITDA margin -100.0% decreased compared to 100.0% same period last year
- EV/Sales multiple is 3.6x
The company showed EPS -$0.01 per share
------------------------------------------------
#reports #FSEA
[First Seacoast Bancorp](https://eninvs.com/company%5fUS%5fwide.php?name=FSEA) (Banks — Regional) reported for 2022 q2
(2022-05-13):
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +7.4%)
- Net Income margin 125.0% increased compared to 25.0% same period last year
- P/E multiple is 6.9x compared to historical level (75th percentile) of 46.0x
- P/S multiple is 3.9x
- Price to book: 1.1x
The company showed EPS +$0.66 per share
------------------------------------------------
#reports #FOXA
[Fox (A)](https://eninvs.com/company%5fUS%5fwide.php?name=FOXA) (Media company) reported for 2022 q2
(2022-08-10, Before Market Open):
- Revenue +4.9% YoY (vs +7.5% in previous quarter and historical rate +7.3%)
- EBITDA +14.0% YoY (vs -36.6% in previous quarter and historical rate +6.2%)
- EBITDA margin 26.8% increased compared to 24.6% same period last year
- Net Debt decreased by $565.0 mln over the past reporting period (2.9% of market cap)
- FCF (LTM) +$1.6 bln (positive), 8.3% of market cap
- EV/EBITDA multiple is 7.9x compared to historical level (75th percentile) of 9.4x
- EV/Sales multiple is 1.5x
The company showed EPS +$0.74 per share vs analyst consensus of +$0.75. At the opening of the session the share price went up +3.1% vs S&P500 +1.4%
------------------------------------------------
#reports #FOX
[Fox](https://eninvs.com/company%5fUS%5fwide.php?name=FOX) (Media company) reported for 2022 q2
(2022-08-10, Before Market Open):
- Revenue +4.9% YoY (vs +7.5% in previous quarter and historical rate +7.3%)
- EBITDA +14.0% YoY (vs -36.6% in previous quarter and historical rate +6.2%)
- EBITDA margin 26.8% increased compared to 24.6% same period last year
- Net Debt decreased by $1.1 bln over the past reporting period (5.4% of market cap)
- FCF (LTM) +$1.9 bln (positive), 9.6% of market cap
- EV/EBITDA multiple is 7.9x compared to historical level (75th percentile) of 9.1x
- EV/Sales multiple is 1.5x
The company showed EPS +$0.57 per share. At the opening of the session the share price went up +2.1% vs S&P500 +1.4%
------------------------------------------------
#reports #EPSN
[Epsilon Energy](https://eninvs.com/company%5fUS%5fwide.php?name=EPSN) (Oil and Gas E and P) reported for 2022 q2
(2022-08-11):
- Revenue +150.0% YoY (vs +133.3% in previous quarter and historical rate +31.9%)
- EBITDA +200.0% YoY (vs +350.0% in previous quarter)
- EBITDA margin 90.0% increased compared to 75.0% same period last year
- Net Debt decreased by $1.0 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) +$0.0 bln (positive), 4.0% of market cap
- EV/EBITDA multiple is 3.7x compared to historical level (75th percentile) of 13.0x
- EV/Sales multiple is 2.2x
The company showed EPS +$0.44 per share
------------------------------------------------
#reports #XPOF
[Xponential Fitness, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=XPOF) (Leisure) reported for 2022 q2:
- Revenue +66.7% YoY (vs +72.4% in previous quarter and historical rate +71.4%)
- EBITDA -100.0% YoY (vs -250.0% in previous quarter and historical rate -33.3%)
- Net Debt decreased by $34.0 mln over the past reporting period (4.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 8.6% of market cap
- EV/EBITDA multiple is 21.3x compared to historical level (75th percentile) of 175.4x
- EV/Sales multiple is 4.5x
The company showed EPS +$0.27 per share. On post-market the stock shows a growth by +1.3% vs S&P500 +0.5%
------------------------------------------------
#reports #XBIO
[Xenetic Biosciences](https://eninvs.com/company%5fUS%5fwide.php?name=XBIO) (Biotechnology) reported for 2022 q2:
- EBITDA margin -300.0% decreased compared to -100.0% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (7.9% of market cap)
- FCF (LTM) +$0.0 bln (positive), 71.4% of market cap
- EV/EBITDA multiple is 0.3x compared to historical level (75th percentile) of 1.2x
- EV/Sales multiple is -2.4x
The company showed EPS -$0.19 per share
------------------------------------------------
#reports #WWW
[Wolverine World Wide](https://eninvs.com/company%5fUS%5fwide.php?name=WWW) (Clothing/shoes/accessories manufacturer) reported for 2022 q2:
- Revenue +13.0% YoY (vs +20.4% in previous quarter and historical rate +8.9%)
- EBITDA +159.2% YoY (vs -52.4% in previous quarter and historical rate +4.6%)
- EBITDA margin 25.8% increased compared to 11.2% same period last year
- Net Debt decreased by $328.0 mln over the past reporting period (17.9% of market cap)
- FCF (LTM) -$0.1 bln (negative), 3.3% of market cap
- EV/EBITDA multiple is 9.1x compared to historical level (75th percentile) of 22.9x
- EV/Sales multiple is 1.0x
The company showed EPS +$0.66 per share vs analyst consensus of +$0.65. At the opening of the session the share price went up +0.1% vs S&P500 +1.4%
------------------------------------------------
#reports #VTSI
[VirTra](https://eninvs.com/company%5fUS%5fwide.php?name=VTSI) (Aerospace and Defense) reported for 2022 q1:
- Revenue +75.0% YoY (vs +28.6% in previous quarter and historical rate +26.2%)
- EBITDA margin 14.3% decreased compared to 25.0% same period last year
- Net Debt increased by $4.0 mln over the past reporting period (6.9% of market cap)
- FCF (LTM) +$0.0 bln (positive), 20.8% of market cap
- EV/EBITDA multiple is 10.7x compared to historical level (75th percentile) of 24.0x
- EV/Sales multiple is 1.6x
The company showed EPS +$0.05 per share
------------------------------------------------
#reports #VIVE
[Viveve Medical](https://eninvs.com/company%5fUS%5fwide.php?name=VIVE) (Medical Devices) reported for 2022 q2:
- Revenue 0.0% YoY (vs +100.0% in previous quarter and historical rate +14.9%)
- EBITDA margin -250.0% has not changed compared to -250.0% same period last year
- EV/Sales multiple is -0.0x
The company showed EPS -$0.67 per share vs analyst consensus of -$0.97. On post-market the stock shows a decrease by -4.0% vs S&P500 +0.5%
------------------------------------------------
#reports #USFD
[US Foods](https://eninvs.com/company%5fUS%5fwide.php?name=USFD) (Food services provider) reported for 2022 q2
(2022-08-09, Before Market Open):
- Revenue +15.2% YoY (vs +23.9% in previous quarter and historical rate +11.7%)
- EBITDA -32.7% YoY (vs +14.2% in previous quarter and historical rate +13.1%)
- EBITDA margin 1.7% decreased compared to 2.8% same period last year
- Net Debt decreased by $194.0 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) +$0.5 bln (positive), 6.5% of market cap
- EV/EBITDA multiple is 18.6x compared to historical level (75th percentile) of 20.3x
- EV/Sales multiple is 0.4x
The company showed EPS +$0.27 per share vs analyst consensus of +$0.24. At the opening of the session the share price went up +0.7% vs S&P500 +0.4%
------------------------------------------------
#reports #UFAB
[Unique Fabricating](https://eninvs.com/company%5fUS%5fwide.php?name=UFAB) (Auto Parts) reported for 2022 q2:
- Revenue +12.9% YoY (vs 0.0% in previous quarter and historical rate -0.9%)
- EBITDA margin 2.9% increased compared to -3.2% same period last year
- Net Debt decreased by $19.0 mln over the past reporting period (129.5% of market cap)
- FCF (LTM) +$0.0 bln (positive), 184.1% of market cap
- EV/Sales multiple is 0.3x
The company showed EPS -$0.91 per share vs analyst consensus of -$0.10
------------------------------------------------
#reports #STON
[StoneMor](https://eninvs.com/company%5fUS%5fwide.php?name=STON) (Personal Services) reported for 2022 q2:
- Revenue -3.6% YoY (vs +3.8% in previous quarter and historical rate +2.6%)
- Net Debt increased by $2.0 mln over the past reporting period (0.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 4.5% of market cap
- EV/Sales multiple is 2.3x
The company showed EPS -$0.15 per share vs analyst consensus of -$0.14. On post-market the stock shows a growth by +0.9% vs S&P500 +0.5%
------------------------------------------------
#reports #SMSI
[Smith Micro Software](https://eninvs.com/company%5fUS%5fwide.php?name=SMSI) (Software — Application) reported for 2022 q2:
- Revenue -18.8% YoY (vs +18.2% in previous quarter and historical rate +23.9%)
- EBITDA margin -53.8% decreased compared to -12.5% same period last year
- Net Debt increased by $4.0 mln over the past reporting period (2.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 14.3% of market cap
- EV/Sales multiple is 2.9x
The company showed EPS -$0.15 per share vs analyst consensus of -$0.06. On post-market the stock shows a decrease by -21.7% vs S&P500 +0.5%
------------------------------------------------
#reports #SIEN
[Sientra](https://eninvs.com/company%5fUS%5fwide.php?name=SIEN) (Medical Devices) reported for 2022 q2:
- Revenue +10.0% YoY (vs -8.7% in previous quarter and historical rate +8.1%)
- EBITDA margin -63.6% decreased compared to -40.0% same period last year
- Net Debt increased by $20.0 mln over the past reporting period (26.2% of market cap)
- FCF (LTM) -$0.1 bln (negative), 89.0% of market cap
- EV/Sales multiple is 1.5x
The company showed EPS -$0.29 per share. On post-market the stock shows a decrease by -9.0% vs S&P500 +0.5%
------------------------------------------------
#reports #RXDX
[Prometheus Biosciences, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=RXDX) (Biotechnology) reported for 2022 q2:
- Revenue 0.0% YoY (vs +300.0% in previous quarter and historical rate +133.3%)
- EBITDA margin -3400.0% decreased compared to -1900.0% same period last year
- Net Debt increased by $131.0 mln over the past reporting period (7.1% of market cap)
- FCF (LTM) -$0.2 bln (negative), 11.7% of market cap
- EV/Sales multiple is 294.2x
The company showed EPS -$0.86 per share vs analyst consensus of -$0.91
------------------------------------------------
#reports #RKDA
[Arcadia Biosciences](https://eninvs.com/company%5fUS%5fwide.php?name=RKDA) (Agricultural Inputs) reported for 2022 q2:
- Revenue +300.0% YoY (vs +200.0% in previous quarter and historical rate +94.0%)
- EBITDA margin -100.0% increased compared to -500.0% same period last year
- Net Debt increased by $3.0 mln over the past reporting period (14.2% of market cap)
- FCF (LTM) -$0.0 bln (negative), 199.2% of market cap
- EV/Sales multiple is 0.2x
The company showed EPS -$0.20 per share vs analyst consensus of -$0.30. On post-market the stock shows a growth by +3.2% vs S&P500 +0.5%
------------------------------------------------
#reports #RIBT
[RiceBran Technologies](https://eninvs.com/company%5fUS%5fwide.php?name=RIBT) (Packaged Foods) reported for 2022 q2:
- Revenue +11.1% YoY (vs +57.1% in previous quarter and historical rate +32.6%)
- EBITDA margin -20.0% decreased compared to 11.1% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (11.2% of market cap)
- FCF (LTM) +$0.0 bln (positive), 16.8% of market cap
- EV/Sales multiple is 0.6x
The company showed EPS -$0.05 per share vs analyst consensus of -$0.03. On post-market the stock shows a decrease by -6.7% vs S&P500 +0.5%
------------------------------------------------
#reports #PTE
[PolarityTE](https://eninvs.com/company%5fUS%5fwide.php?name=PTE) (Biotechnology) reported for 2022 q2:
- EBITDA margin -600.0% decreased compared to -266.7% same period last year
- Net Debt decreased by $4.0 mln over the past reporting period (51.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 129.5% of market cap
- EV/EBITDA multiple is 0.5x compared to historical level (75th percentile) of 0.3x
- EV/Sales multiple is -4.1x
The company showed EPS -$1.30 per share vs analyst consensus of -$1.25. On post-market the stock shows a decrease by -14.8% vs S&P500 +0.5%
------------------------------------------------
#reports #PRPO
[Precipio](https://eninvs.com/company%5fUS%5fwide.php?name=PRPO) (Diagnostics and Research) reported for 2022 q2:
- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +29.2%)
- EBITDA margin -100.0% decreased compared to -50.0% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (5.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 25.9% of market cap
- EV/Sales multiple is 4.1x
The company showed EPS -$0.09 per share vs analyst consensus of -$0.28
------------------------------------------------
#reports #POSH
[Poshmark, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=POSH) (Internet Retail) reported for 2022 q2:
- Revenue +8.5% YoY (vs +12.3% in previous quarter and historical rate +14.6%)
- Net Debt increased by $14.0 mln over the past reporting period (1.4% of market cap)
- FCF (LTM) +$0.0 bln (positive), 1.1% of market cap
- EV/Sales multiple is 1.3x
The company showed EPS -$0.29 per share vs analyst consensus of -$0.27. On post-market the stock shows a decrease by -5.3% vs S&P500 +0.5%
------------------------------------------------
#reports #POAI
[Predictive Oncology](https://eninvs.com/company%5fUS%5fwide.php?name=POAI) (Medical Instruments and Supplies) reported for 2022 q2:
- EBITDA margin -200.0% has not changed compared to -200.0% same period last year
- Net Debt decreased by $4.0 mln over the past reporting period (10.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 41.8% of market cap
- EV/Sales multiple is 10.3x
------------------------------------------------
#reports #PDLB
[PDL Community Bancorp](https://eninvs.com/company%5fUS%5fwide.php?name=PDLB) (Banks — Regional) reported for 2022 q2:
- Revenue 0.0% YoY (vs +26.7% in previous quarter and historical rate +23.9%)
- Net Income +200.0% YoY (vs +750.0% in previous quarter)
- Net Income margin 105.9% increased compared to 35.3% same period last year
- P/S multiple is 3.4x
- Price to book: 0.8x
The company showed EPS +$0.03 per share vs analyst consensus of +$0.04
------------------------------------------------
#reports #PDFS
[PDF Solutions](https://eninvs.com/company%5fUS%5fwide.php?name=PDFS) (Software — Application) reported for 2022 q2:
- Revenue +29.6% YoY (vs +37.5% in previous quarter and historical rate +16.8%)
- EBITDA margin 2.9% increased compared to -3.7% same period last year
- Net Debt decreased by $45.0 mln over the past reporting period (4.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.5% of market cap
- EV/Sales multiple is 7.3x
The company showed EPS +$0.11 per share vs analyst consensus of +$0.07. On post-market the stock shows a growth by +5.9% vs S&P500 +0.5%
------------------------------------------------
#reports #OSS
[One Stop Systems](https://eninvs.com/company%5fUS%5fwide.php?name=OSS) (Computer Hardware) reported for 2022 q2:
- Revenue +38.5% YoY (vs +21.4% in previous quarter and historical rate +25.9%)
- EBITDA margin 5.6% decreased compared to 7.7% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (1.3% of market cap)
- FCF (LTM) -$0.0 bln (negative), 17.8% of market cap
- EV/EBITDA multiple is 16.1x compared to historical level (75th percentile) of 32.3x
- EV/Sales multiple is 1.2x
The company showed EPS +$0.02 per share
------------------------------------------------
#reports #OSCR
[Oscar Health, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=OSCR) (Healthcare Plans) reported for 2022 q2:
- Revenue +84.9% YoY (vs +159.9% in previous quarter and historical rate +140.5%)
- P/S multiple is 0.4x
- Price to book: 1.0x
The company showed EPS -$0.53 per share. On post-market the stock shows a growth by +3.5% vs S&P500 +0.5%
------------------------------------------------
#reports #OPNT
[Opiant Pharmaceuticals](https://eninvs.com/company%5fUS%5fwide.php?name=OPNT) (Biotechnology) reported for 2022 q2:
- Revenue -33.3% YoY (vs -80.0% in previous quarter and historical rate +35.4%)
- EBITDA margin -275.0% decreased compared to -33.3% same period last year
- Net Debt increased by $8.0 mln over the past reporting period (12.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 14.1% of market cap
- EV/Sales multiple is 1.2x
The company showed EPS -$2.31 per share vs analyst consensus of -$1.36. On post-market the stock shows a growth by +4.9% vs S&P500 +0.5%
------------------------------------------------
#reports #OLO
[Olo Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=OLO) (Software — Application) reported for 2022 q2:
- Revenue +27.8% YoY (vs +19.4% in previous quarter and historical rate +25.4%)
- EBITDA margin -19.6% decreased compared to -5.6% same period last year
- Net Debt increased by $76.0 mln over the past reporting period (3.8% of market cap)
- FCF (LTM) -$0.2 bln (negative), 10.3% of market cap
- EV/Sales multiple is 10.0x
The company showed EPS -$0.07 per share. On post-market the stock shows a decrease by -27.3% vs S&P500 +0.5%
------------------------------------------------
#reports #NEON
[Neonode](https://eninvs.com/company%5fUS%5fwide.php?name=NEON) (Electronic Components) reported for 2022 q2
(2022-08-11, Before Market Open):
- Revenue -50.0% YoY (vs -50.0% in previous quarter and historical rate -8.3%)
- EBITDA margin -100.0% decreased compared to -50.0% same period last year
- Net Debt increased by $3.0 mln over the past reporting period (5.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 10.0% of market cap
- EV/Sales multiple is 12.0x
The company showed EPS -$0.11 per share vs analyst consensus of -$0.06. At the opening of the session the share price went down -0.8% vs S&P500 +0.4%
------------------------------------------------
#reports #MTEM
[Molecular Templates](https://eninvs.com/company%5fUS%5fwide.php?name=MTEM) (Biotechnology) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue -73.3% YoY (vs +166.7% in previous quarter and historical rate +21.4%)
- EBITDA margin -100.0% decreased compared to -86.7% same period last year
- Net Debt decreased by $85.0 mln over the past reporting period (171.8% of market cap)
- FCF (LTM) -$0.1 bln (negative), 186.0% of market cap
- EV/Sales multiple is -0.3x
On post-market the stock shows a decrease by -2.8% vs S&P500 +0.5%
------------------------------------------------
#reports #MOTS
[Motus GI](https://eninvs.com/company%5fUS%5fwide.php?name=MOTS) (Diagnostics and Research) reported for 2022 q2
(2022-08-11, After Market Close):
- EBITDA margin -400.0% increased compared to -500.0% same period last year
- EV/Sales multiple is 3.3x
The company showed EPS -$1.86 per share vs analyst consensus of -$2.01. On post-market the stock shows a decrease by -2.2% vs S&P500 +0.5%
------------------------------------------------
#reports #MCW
[Mister Car Wash, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=MCW) (Personal Services) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue +14.2% YoY (vs +24.4% in previous quarter and historical rate +18.8%)
- EBITDA margin 28.0% increased compared to -65.5% same period last year
- Net Debt increased by $3.0 mln over the past reporting period (0.1% of market cap)
- FCF (LTM) -$0.4 bln (negative), 10.7% of market cap
- EV/EBITDA multiple is 21.4x compared to historical level (75th percentile) of 136.0x
- EV/Sales multiple is 6.3x
The company showed EPS +$0.11 per share vs analyst consensus of +$0.12. On post-market the stock shows a decrease by -11.8% vs S&P500 +0.5%
------------------------------------------------
#reports #LAW
[CS Disco, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=LAW) (Software — Application) reported for 2022 q2:
- Revenue +13.3% YoY (vs +61.9% in previous quarter and historical rate +51.4%)
- Net Debt increased by $10.0 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$0.2 bln (positive), 11.4% of market cap
- EV/Sales multiple is 11.1x
The company showed EPS -$0.35 per share vs analyst consensus of -$0.27. On post-market the stock shows a decrease by -20.2% vs S&P500 +0.5%
------------------------------------------------
#reports #ICCC
[ImmuCell Corporation](https://eninvs.com/company%5fUS%5fwide.php?name=ICCC) (Biotechnology) reported for 2022 q2:
- Revenue -20.0% YoY (vs +50.0% in previous quarter and historical rate +22.4%)
- Net Debt decreased by $11.0 mln over the past reporting period (16.2% of market cap)
- FCF (LTM) +$0.0 bln (positive), 22.1% of market cap
- EV/EBITDA multiple is 28.4x compared to historical level (75th percentile) of 45.0x
- EV/Sales multiple is 2.8x
The company showed EPS -$0.08 per share. On post-market the stock shows a decrease by -9.7% vs S&P500 +0.5%
------------------------------------------------
#reports #HMPT
[Home Point Capital Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=HMPT) (Mortgage Finance) reported for 2022 q2
(2022-08-11, Before Market Open):
- Revenue +18.6% YoY (vs -63.4% in previous quarter and historical rate -39.2%)
- Net Income margin 1.4% increased compared to -123.7% same period last year
- P/E multiple is 1.7x compared to historical level (75th percentile) of 2.4x
- P/S multiple is 0.8x
- Price to book: 0.7x
The company showed EPS -$0.32 per share vs analyst consensus of -$0.05. At the opening of the session the share price went down -3.0% vs S&P500 +0.4%
------------------------------------------------
#reports #GTIM
[Good Times Restaurants](https://eninvs.com/company%5fUS%5fwide.php?name=GTIM) (Restaurants) reported for 2022 q2:
- Revenue +5.9% YoY (vs +17.2% in previous quarter and historical rate +17.0%)
- EBITDA -75.0% YoY (vs -100.0% in previous quarter and historical rate +22.9%)
- EBITDA margin 2.8% decreased compared to 11.8% same period last year
- Net Debt decreased by $56.0 mln over the past reporting period (128.0% of market cap)
- FCF (LTM) +$0.1 bln (positive), 128.0% of market cap
- EV/EBITDA multiple is 11.2x compared to historical level (75th percentile) of 13.5x
- EV/Sales multiple is 0.2x
The company showed EPS +$0.04 per share
------------------------------------------------
#reports #FSBC
[Five Star Bancorp](https://eninvs.com/company%5fUS%5fwide.php?name=FSBC) (Banks — Regional) reported for 2022 q2:
- Revenue +25.0% YoY (vs +26.3% in previous quarter and historical rate +18.6%)
- Net Income +190.0% YoY (vs +50.0% in previous quarter and historical rate +98.5%)
- Net Income margin 116.0% increased compared to 50.0% same period last year
- P/S multiple is 4.8x
- Price to book: 1.9x
The company showed EPS +$0.58 per share vs analyst consensus of +$0.54
------------------------------------------------
#reports #FOSL
[Fossil Group](https://eninvs.com/company%5fUS%5fwide.php?name=FOSL) (Luxury Goods) reported for 2022 q2
(2022-08-10, After Market Close):
- Revenue +2.2% YoY (vs -28.8% in previous quarter and historical rate -8.8%)
- EBITDA margin -0.3% increased compared to -1.7% same period last year
- Net Debt increased by $59.0 mln over the past reporting period (18.5% of market cap)
- FCF (LTM) -$0.3 bln (negative), 84.8% of market cap
- EV/EBITDA multiple is 7.4x compared to historical level (75th percentile) of 10.1x
- EV/Sales multiple is 0.4x
The company showed EPS -$0.37 per share vs analyst consensus of -$2.52. At the opening of the session the share price went down -6.8% vs S&P500 +0.4%
------------------------------------------------
#reports #FDMT
[4D Molecular Therapeutics, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=FDMT) (Biotechnology) reported for 2022 q2
(2022-08-11, After Market Close):
- EBITDA margin -2800.0% decreased compared to -46.7% same period last year
- Net Debt decreased by $37.0 mln over the past reporting period (11.0% of market cap)
- FCF (LTM) -$0.1 bln (negative), 44.1% of market cap
- EV/Sales multiple is 120.0x
The company showed EPS -$0.87 per share vs analyst consensus of -$0.85
------------------------------------------------
#reports #FBIOP
[Fortress Biotech](https://eninvs.com/company%5fUS%5fwide.php?name=FBIOP) (Biotechnology) reported for 2022 q2:
- Revenue 0.0% YoY (vs +100.0% in previous quarter and historical rate +47.2%)
- EBITDA margin -272.2% decreased compared to -233.3% same period last year
- Net Debt increased by $28.0 mln over the past reporting period (24.6% of market cap)
- FCF (LTM) -$0.0 bln (negative), 40.4% of market cap
- EV/EBITDA multiple is 0.3x compared to historical level (75th percentile) of 0.7x
- EV/Sales multiple is -0.4x
The company showed EPS -$0.24 per share
------------------------------------------------
#reports #DIBS
[1stdibs.Com, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=DIBS) (Internet Retail) reported for 2022 q2:
- Revenue 0.0% YoY (vs +3.8% in previous quarter and historical rate +5.4%)
- EBITDA margin 4.0% increased compared to -12.0% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (0.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 14.6% of market cap
- EV/Sales multiple is 1.2x
The company showed EPS -$0.01 per share vs analyst consensus of -$0.23. At the opening of the session the share price went down -5.3% vs S&P500 +1.4%
------------------------------------------------
#reports #CWBC
[Community West Bancshares](https://eninvs.com/company%5fUS%5fwide.php?name=CWBC) (Banks — Regional) reported for 2022 q2:
- Revenue 0.0% YoY (vs +9.1% in previous quarter and historical rate +10.6%)
- Net Income +225.0% YoY (vs +100.0% in previous quarter and historical rate +70.8%)
- Net Income margin 108.3% increased compared to 33.3% same period last year
- P/E multiple is 4.2x compared to historical level (75th percentile) of 11.1x
- P/S multiple is 2.5x
- Price to book: 1.1x
The company showed EPS +$0.30 per share vs analyst consensus of +$0.32
------------------------------------------------
#reports #CORR
[CorEnergy Infrastructure Trust](https://eninvs.com/company%5fUS%5fwide.php?name=CORR) (Real estate investment fund) reported for 2022 q2:
- Revenue 0.0% YoY (vs +43.5% in previous quarter and historical rate +40.5%)
- EBITDA -40.0% YoY (vs +200.0% in previous quarter and historical rate +22.6%)
- EBITDA margin 18.8% decreased compared to 31.3% same period last year
- Net Debt decreased by $5.0 mln over the past reporting period (13.0% of market cap)
- FCF (LTM) +$0.1 bln (positive), 292.2% of market cap
- EV/EBITDA multiple is 4.9x compared to historical level (75th percentile) of 16.6x
- EV/Sales multiple is 1.0x
The company showed EPS -$0.08 per share vs analyst consensus of +$0.56. At the opening of the session the share price went up +3.8% vs S&P500 +0.4%
------------------------------------------------
#reports #CODX
[Co-Diagnostics](https://eninvs.com/company%5fUS%5fwide.php?name=CODX) (Diagnostics and Research) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue -81.5% YoY (vs +15.0% in previous quarter and historical rate +79.7%)
- EBITDA -116.7% YoY (vs +30.0% in previous quarter)
- EBITDA margin -40.0% decreased compared to 44.4% same period last year
- Net Debt increased by $11.0 mln over the past reporting period (5.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 8.7% of market cap
- EV/EBITDA multiple is 3.8x compared to historical level (75th percentile) of 8.1x
- EV/Sales multiple is 1.7x
The company showed EPS -$0.08 per share vs analyst consensus of +$0.10
------------------------------------------------
#reports #CDRE
[Cadre Holdings, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=CDRE) (Aerospace and Defense) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue +2.6% YoY (vs -6.3% in previous quarter and historical rate -2.5%)
- EBITDA -38.9% YoY (vs -157.9% in previous quarter and historical rate -86.1%)
- EBITDA margin 9.3% decreased compared to 15.7% same period last year
- Net Debt decreased by $22.0 mln over the past reporting period (2.3% of market cap)
- FCF (LTM) +$0.1 bln (positive), 7.1% of market cap
- EV/EBITDA multiple is 268.0x compared to historical level (75th percentile) of 80.9x
- EV/Sales multiple is 2.5x
The company showed EPS +$0.12 per share vs analyst consensus of +$0.20. On post-market the stock shows a decrease by -1.6% vs S&P500 +0.5%
------------------------------------------------
#reports #CCU
[Compañía Cervecerías Unidas](https://eninvs.com/company%5fUS%5fwide.php?name=CCU) (Beverages — Brewers) reported for 2022 q2:
- Revenue -2.5% YoY (vs +1.2% in previous quarter and historical rate +8.6%)
- EBITDA -121.4% YoY (vs -20.6% in previous quarter and historical rate -3.1%)
- EBITDA margin -1.4% decreased compared to 6.5% same period last year
- Net Debt increased by $326.0 mln over the past reporting period (16.0% of market cap)
- FCF (LTM) -$0.3 bln (negative), 14.6% of market cap
- EV/EBITDA multiple is 10.4x compared to historical level (75th percentile) of 13.7x
- EV/Sales multiple is 0.9x
The company showed EPS -$56.60 per share vs analyst consensus of +$0.07. At the opening of the session the share price went down -1.7% vs S&P500 0.0%
------------------------------------------------
#reports #CALB
[California BanCorp](https://eninvs.com/company%5fUS%5fwide.php?name=CALB) (Banks — Regional) reported for 2022 q2:
- Revenue +20.0% YoY (vs +21.4% in previous quarter and historical rate +24.2%)
- Net Income +400.0% YoY (vs +133.3% in previous quarter and historical rate +74.6%)
- Net Income margin 111.1% increased compared to 26.7% same period last year
- P/E multiple is 4.4x compared to historical level (75th percentile) of 16.2x
- P/S multiple is 2.7x
- Price to book: 1.1x
The company showed EPS +$0.51 per share vs analyst consensus of +$0.40
------------------------------------------------
#reports #BSBK
[Bogota Financial](https://eninvs.com/company%5fUS%5fwide.php?name=BSBK) (Banks — Regional) reported for 2022 q2:
- Revenue +40.0% YoY (vs 0.0% in previous quarter and historical rate +34.1%)
- Net Income margin 100.0% increased compared to 20.0% same period last year
- P/E multiple is 10.3x compared to historical level (75th percentile) of 50.0x
- P/S multiple is 7.1x
- Price to book: 1.2x
The company showed EPS +$0.12 per share vs analyst consensus of +$0.12
------------------------------------------------
#reports #BOXL
[Boxlight Corporation](https://eninvs.com/company%5fUS%5fwide.php?name=BOXL) (Communication Equipment) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue +27.7% YoY (vs +54.5% in previous quarter and historical rate +70.8%)
- EBITDA 0.0% YoY (vs -100.0% in previous quarter)
- EBITDA margin 5.0% decreased compared to 6.4% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (2.2% of market cap)
- FCF (LTM) -$0.0 bln (negative), 71.9% of market cap
- EV/EBITDA multiple is 9.2x compared to historical level (75th percentile) of 9.9x
- EV/Sales multiple is 0.4x
The company showed EPS -$0.00 per share vs analyst consensus of -$0.07. On post-market the stock shows a growth by +10.2% vs S&P500 +0.5%
------------------------------------------------
#reports #BNTX
[BioNTech](https://eninvs.com/company%5fUS%5fwide.php?name=BNTX) (Biotechnology) reported for 2022 q2:
- Revenue -48.4% YoY (vs +166.7% in previous quarter and historical rate +158.2%)
- EBITDA -52.1% YoY (vs +158.3% in previous quarter and historical rate +138.3%)
- EBITDA margin 73.8% decreased compared to 79.4% same period last year
- Net Debt decreased by $3.2 bln over the past reporting period (8.4% of market cap)
- FCF (LTM) +$9.4 bln (positive), 24.4% of market cap
- EV/EBITDA multiple is 1.6x compared to historical level (75th percentile) of 12.1x
- EV/Sales multiple is 1.3x
The company showed EPS +$6.58 per share vs analyst consensus of +$7.23. At the opening of the session the share price went down -8.8% vs S&P500 +0.3%
------------------------------------------------
#reports #BIOL
[BIOLASE](https://eninvs.com/company%5fUS%5fwide.php?name=BIOL) (Medical Devices) reported for 2022 q2:
- Revenue +33.3% YoY (vs +25.0% in previous quarter and historical rate +17.0%)
- EBITDA margin -41.7% decreased compared to -33.3% same period last year
- Net Debt decreased by $12.0 mln over the past reporting period (35.1% of market cap)
- FCF (LTM) -$0.0 bln (negative), 11.7% of market cap
- EV/Sales multiple is 0.4x
The company showed EPS -$0.91 per share vs analyst consensus of -$0.62. On post-market the stock shows a growth by +8.1% vs S&P500 +0.5%
------------------------------------------------
#reports #BCE
[BCE](https://eninvs.com/company%5fUS%5fwide.php?name=BCE) (Telecom Services) reported for 2022 q2
(2022-08-04, Before Market Open):
- Revenue -0.3% YoY (vs +1.3% in previous quarter and historical rate -6.8%)
- EBITDA -5.0% YoY (vs +25.4% in previous quarter and historical rate -1.0%)
- EBITDA margin 39.8% decreased compared to 41.7% same period last year
- Net Debt decreased by $106.0 mln over the past reporting period (0.2% of market cap)
- FCF (LTM) +$0.5 bln (positive), 1.0% of market cap
- EV/EBITDA multiple is 8.9x compared to historical level (75th percentile) of 9.5x
- EV/Sales multiple is 3.7x
The company showed EPS +$0.67 per share vs analyst consensus of +$0.65. At the opening of the session the share price went up +0.2% vs S&P500 0.0%
------------------------------------------------
#reports #AZYO
[Aziyo Biologics](https://eninvs.com/company%5fUS%5fwide.php?name=AZYO) (Medical Devices) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue 0.0% YoY (vs -8.3% in previous quarter and historical rate +4.2%)
- EBITDA margin -61.5% decreased compared to -23.1% same period last year
- Net Debt increased by $23.0 mln over the past reporting period (24.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 27.6% of market cap
- EV/Sales multiple is 2.5x
------------------------------------------------
#reports #AVGR
[Avinger](https://eninvs.com/company%5fUS%5fwide.php?name=AVGR) (Medical Devices) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue -33.3% YoY (vs -33.3% in previous quarter and historical rate +15.3%)
- EBITDA margin -200.0% decreased compared to -133.3% same period last year
- Net Debt increased by $4.0 mln over the past reporting period (41.2% of market cap)
- FCF (LTM) -$0.0 bln (negative), 72.1% of market cap
- EV/Sales multiple is 0.6x
On post-market the stock shows a growth by +0.6% vs S&P500 +0.5%
------------------------------------------------
#reports #AUTO
[AutoWeb](https://eninvs.com/company%5fUS%5fwide.php?name=AUTO) (Internet Content and Information) reported for 2022 q2:
- Revenue -10.5% YoY (vs +5.6% in previous quarter and historical rate -15.0%)
- EBITDA margin -17.6% decreased compared to 5.3% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (18.3% of market cap)
- FCF (LTM) +$0.0 bln (positive), 275.1% of market cap
- EV/Sales multiple is 0.1x
The company showed EPS -$0.34 per share vs analyst consensus of -$0.11
------------------------------------------------
#reports #ATGE
[Adtalem Global Education](https://eninvs.com/company%5fUS%5fwide.php?name=ATGE) (Commercial higher education institutions owner ) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue +28.9% YoY (vs +30.2% in previous quarter and historical rate +6.9%)
- EBITDA +156.5% YoY (vs +538.5% in previous quarter and historical rate +55.1%)
- EBITDA margin 44.0% increased compared to 22.1% same period last year
- Net Debt increased by $43.0 mln over the past reporting period (2.5% of market cap)
- FCF (LTM) +$0.2 bln (positive), 11.7% of market cap
- EV/EBITDA multiple is 3.7x compared to historical level (75th percentile) of 16.5x
- EV/Sales multiple is 1.7x
The company showed EPS +$0.18 per share vs analyst consensus of +$1.25
------------------------------------------------
#reports #APYX
[Apyx Medical Corporation](https://eninvs.com/company%5fUS%5fwide.php?name=APYX) (Medical Devices) reported for 2022 q2:
- Revenue +11.1% YoY (vs +9.1% in previous quarter and historical rate +34.1%)
- EBITDA margin -50.0% increased compared to -55.6% same period last year
- Net Debt increased by $27.0 mln over the past reporting period (7.6% of market cap)
- FCF (LTM) -$0.0 bln (negative), 9.9% of market cap
- EV/Sales multiple is 7.9x
The company showed EPS -$0.16 per share vs analyst consensus of -$0.19. On post-market the stock shows a decrease by -2.7% vs S&P500 +0.5%
------------------------------------------------
#reports #APDN
[Applied DNA Sciences](https://eninvs.com/company%5fUS%5fwide.php?name=APDN) (Diagnostics and Research) reported for 2022 q2
(2022-08-10, After Market Close):
- Revenue +100.0% YoY (vs +100.0% in previous quarter and historical rate +75.0%)
- EBITDA margin -25.0% increased compared to -150.0% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (5.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 18.9% of market cap
- EV/Sales multiple is 1.9x
The company showed EPS -$0.13 per share vs analyst consensus of -$0.35. On post-market the stock shows a growth by +0.4% vs S&P500 +0.5%
------------------------------------------------
#reports #AMYT
[Amryt Pharma plc](https://eninvs.com/company%5fUS%5fwide.php?name=AMYT) (Drug Manufacturers — Specialty and Generic) reported for 2022 q2
(2022-08-04):
- Revenue +9.5% YoY (vs +22.9% in previous quarter and historical rate +13.4%)
- EBITDA -33.3% YoY (vs -80.0% in previous quarter and historical rate +41.0%)
- EBITDA margin 11.6% decreased compared to 19.0% same period last year
- Net Debt increased by $18.0 mln over the past reporting period (3.6% of market cap)
- FCF (LTM) -$0.1 bln (negative), 13.1% of market cap
- EV/EBITDA multiple is 18.4x compared to historical level (75th percentile) of 15.3x
- EV/Sales multiple is 2.6x
The company showed EPS -$0.10 per share vs analyst consensus of -$0.05. At the opening of the session the share price went down -3.9% vs S&P500 0.0%
------------------------------------------------
#reports #ALT
[Altimmune](https://eninvs.com/company%5fUS%5fwide.php?name=ALT) (Biotechnology) reported for 2022 q2:
- EBITDA margin -2000.0% decreased compared to -1500.0% same period last year
- Net Debt increased by $43.0 mln over the past reporting period (7.2% of market cap)
- FCF (LTM) -$0.0 bln (negative), 3.0% of market cap
- EV/Sales multiple is 459.1x
The company showed EPS -$0.42 per share vs analyst consensus of -$0.29. At the opening of the session the share price went down -0.9% vs S&P500 +0.4%
------------------------------------------------
#reports #ALPN
[Alpine Immune Sciences](https://eninvs.com/company%5fUS%5fwide.php?name=ALPN) (Biotechnology) reported for 2022 q2:
- Revenue +66.7% YoY (vs +133.3% in previous quarter and historical rate +150.0%)
- EBITDA margin -300.0% increased compared to -333.3% same period last year
- Net Debt increased by $10.0 mln over the past reporting period (3.8% of market cap)
- FCF (LTM) +$0.1 bln (positive), 21.1% of market cap
- EV/Sales multiple is 7.2x
The company showed EPS -$0.60 per share vs analyst consensus of -$0.39
------------------------------------------------
#reports #ALJJ
[ALJ Regional](https://eninvs.com/company%5fUS%5fwide.php?name=ALJJ) (Specialty Business Services) reported for 2022 q2:
- Revenue -43.7% YoY (vs -40.0% in previous quarter and historical rate -2.2%)
- Net Income >1000% YoY (vs -100.0% in previous quarter and historical rate -7.7%)
- Net Income margin 198.3% increased compared to 3.9% same period last year
- P/E multiple is 0.8x compared to historical level (75th percentile) of 12.5x
- P/S multiple is 0.3x
- Price to book: 0.6x
The company showed EPS +$1.93 per share
------------------------------------------------
#reports #AIT
[Applied Industrial Technologies](https://eninvs.com/company%5fUS%5fwide.php?name=AIT) (Distributer of industrial products) reported for 2022 q2:
- Revenue +18.4% YoY (vs +16.6% in previous quarter and historical rate +4.0%)
- EBITDA +12.6% YoY (vs +22.5% in previous quarter and historical rate +16.2%)
- EBITDA margin 10.1% decreased compared to 10.6% same period last year
- Net Debt decreased by $717.0 mln over the past reporting period (15.7% of market cap)
- FCF (LTM) -$0.7 bln (negative), 14.4% of market cap
- EV/EBITDA multiple is 11.3x compared to historical level (75th percentile) of 19.9x
- EV/Sales multiple is 1.2x
The company showed EPS +$2.02 per share vs analyst consensus of +$1.66. At the opening of the session the share price went up +9.6% vs S&P500 +0.4%
------------------------------------------------
#reports #AIRG
[Airgain](https://eninvs.com/company%5fUS%5fwide.php?name=AIRG) (Communication Equipment) reported for 2022 q2:
- Revenue +11.8% YoY (vs +5.9% in previous quarter and historical rate +5.0%)
- EBITDA margin 5.3% increased compared to -11.8% same period last year
- Net Debt increased by $9.0 mln over the past reporting period (10.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 12.0% of market cap
- EV/Sales multiple is 1.2x
The company showed EPS -$0.00 per share vs analyst consensus of +$0.01. On post-market the stock shows a growth by +4.0% vs S&P500 +0.5%
------------------------------------------------
#reports #AGRX
[Agile Therapeutics](https://eninvs.com/company%5fUS%5fwide.php?name=AGRX) (Drug Manufacturers — Specialty and Generic) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue +100.0% YoY (vs +100.0% in previous quarter and historical rate +83.3%)
- EBITDA margin -550.0% increased compared to -1600.0% same period last year
- Net Debt decreased by $9.0 mln over the past reporting period (35.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 39.9% of market cap
- EV/Sales multiple is 4.9x
The company showed EPS -$2.71 per share vs analyst consensus of -$3.70. On post-market the stock shows a decrease by -3.8% vs S&P500 +0.5%
------------------------------------------------
#reports #AEY
[ADDvantage Technologies Group](https://eninvs.com/company%5fUS%5fwide.php?name=AEY) (Electronics and Computer Distribution) reported for 2022 q2
(2022-08-11, After Market Close):
- Revenue +64.7% YoY (vs +84.6% in previous quarter and historical rate +35.1%)
- EBITDA margin 3.6% increased compared to -11.8% same period last year
- Net Debt decreased by $1.0 mln over the past reporting period (5.4% of market cap)
- FCF (LTM) +$0.0 bln (positive), 37.6% of market cap
- EV/Sales multiple is 0.2x
The company showed EPS +$0.07 per share. On post-market the stock shows a growth by +39.0% vs S&P500 +0.5%
------------------------------------------------
#reports #AE
[Adams Resources & Energy](https://eninvs.com/company%5fUS%5fwide.php?name=AE) (Oil and Gas Integrated) reported for 2022 q2:
- Revenue +103.7% YoY (vs +138.2% in previous quarter and historical rate +43.8%)
- EBITDA -27.3% YoY (vs +44.4% in previous quarter and historical rate +55.5%)
- EBITDA margin 0.8% decreased compared to 2.3% same period last year
- Net Debt increased by $32.0 mln over the past reporting period (20.9% of market cap)
- FCF (LTM) -$0.0 bln (negative), 4.6% of market cap
- EV/EBITDA multiple is 3.3x compared to historical level (75th percentile) of 5.2x
- EV/Sales multiple is 0.0x
The company showed EPS +$0.56 per share vs analyst consensus of +$0.62. At the opening of the session the share price went down -0.4% vs S&P500 +0.4%
------------------------------------------------
#reports #ACTG
[Acacia Research Corporation](https://eninvs.com/company%5fUS%5fwide.php?name=ACTG) (Specialty Business Services) reported for 2022 q2:
- Revenue 0.0% YoY (vs +133.3% in previous quarter and historical rate +57.0%)
- Net Income -333.3% YoY (vs -8300.0% in previous quarter)
- Net Income margin -329.4% decreased compared to 141.2% same period last year
- P/S multiple is 2.3x
- Price to book: 0.9x
The company showed EPS -$1.40 per share vs analyst consensus of -$0.04. At the opening of the session the share price went down -3.8% vs S&P500 +0.4%
------------------------------------------------
#reports #VERU
[Veru](https://eninvs.com/company%5fUS%5fwide.php?name=VERU) (Biotechnology) reported for 2022 q2:
- Revenue -44.4% YoY (vs 0.0% in previous quarter and historical rate +30.7%)
- Net Debt decreased by $4.0 mln over the past reporting period (0.4% of market cap)
- FCF (LTM) -$0.0 bln (negative), 1.9% of market cap
- EV/Sales multiple is 16.0x
The company showed EPS -$0.28 per share. At the opening of the session the share price went up +46.8% vs S&P500 +0.4%
------------------------------------------------
#reports #URGN
[UroGen Pharma](https://eninvs.com/company%5fUS%5fwide.php?name=URGN) (Biotechnology) reported for 2022 q2:
- Revenue +30.8% YoY (vs +100.0% in previous quarter and historical rate +102.6%)
- EBITDA margin -111.8% increased compared to -169.2% same period last year
- Net Debt increased by $31.0 mln over the past reporting period (15.3% of market cap)
- FCF (LTM) -$0.1 bln (negative), 61.3% of market cap
- EV/Sales multiple is 3.4x
The company showed EPS -$1.18 per share
------------------------------------------------
#reports #SOHO
[Sotherly Hotels](https://eninvs.com/company%5fUS%5fwide.php?name=SOHO) (REIT — Hotel and Motel) reported for 2022 q2:
- Revenue +38.2% YoY (vs +65.2% in previous quarter and historical rate +25.9%)
- EBITDA +233.3% YoY (vs -25.0% in previous quarter)
- EBITDA margin 63.8% increased compared to 26.5% same period last year
- Net Debt decreased by $4.0 mln over the past reporting period (5.0% of market cap)
- FCF (LTM) +$0.4 bln (positive), 485.1% of market cap
- EV/EBITDA multiple is 5.0x compared to historical level (75th percentile) of 43.7x
- EV/Sales multiple is 0.4x
The company showed EPS +$1.38 per share vs analyst consensus of -$0.48. At the opening of the session the share price went up +5.1% vs S&P500 +0.4%
------------------------------------------------
#reports #SMID
[Smith-Midland Corporation](https://eninvs.com/company%5fUS%5fwide.php?name=SMID) (Building Materials) reported for 2022 q2:
- Revenue +8.3% YoY (vs -33.3% in previous quarter and historical rate +4.0%)
- EBITDA 0.0% YoY (vs -75.0% in previous quarter and historical rate +56.3%)
- EBITDA margin 15.4% decreased compared to 16.7% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (2.2% of market cap)
- EV/EBITDA multiple is 9.6x compared to historical level (75th percentile) of 9.0x
- EV/Sales multiple is 1.8x
The company showed EPS +$0.17 per share
------------------------------------------------
#reports #SIX
[Six Flags Entertainment Corporation](https://eninvs.com/company%5fUS%5fwide.php?name=SIX) (Leisure) reported for 2022 q2:
- Revenue -5.4% YoY (vs +68.3% in previous quarter and historical rate +31.4%)
- EBITDA -100.0% YoY (vs -1900.0% in previous quarter and historical rate -1.6%)
- Net Debt increased by $19.0 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) -$0.3 bln (negative), 12.4% of market cap
- EV/EBITDA multiple is 4.8x compared to historical level (75th percentile) of 10.5x
- EV/Sales multiple is 3.2x
The company showed EPS +$0.53 per share vs analyst consensus of -$0.39. At the opening of the session the share price went down -20.4% vs S&P500 +0.4%
------------------------------------------------
#reports #RDNT
[RadNet](https://eninvs.com/company%5fUS%5fwide.php?name=RDNT) (Diagnostics and Research) reported for 2022 q2
(2022-08-09, Before Market Open):
- Revenue +6.0% YoY (vs +8.6% in previous quarter and historical rate +11.1%)
- EBITDA +530.8% YoY (vs +50.0% in previous quarter and historical rate +43.0%)
- EBITDA margin 92.7% increased compared to 15.6% same period last year
- Net Debt increased by $9.0 mln over the past reporting period (0.7% of market cap)
- FCF (LTM) +$0.0 bln (positive), 1.9% of market cap
- EV/EBITDA multiple is 5.5x compared to historical level (75th percentile) of 15.2x
- EV/Sales multiple is 1.9x
The company showed EPS +$0.15 per share vs analyst consensus of +$0.07. At the opening of the session the share price went up +0.2% vs S&P500 -0.2%
------------------------------------------------
#reports #PRMW
[Primo Water Corporation](https://eninvs.com/company%5fUS%5fwide.php?name=PRMW) (Beverages — Non-Alcoholic) reported for 2022 q2:
- Revenue +8.6% YoY (vs +10.0% in previous quarter and historical rate -2.4%)
- EBITDA -3.4% YoY (vs +10.4% in previous quarter and historical rate +10.6%)
- EBITDA margin 9.8% decreased compared to 11.0% same period last year
- Net Debt decreased by $29.0 mln over the past reporting period (1.4% of market cap)
- FCF (LTM) +$0.0 bln (positive), 0.3% of market cap
- EV/EBITDA multiple is 12.8x compared to historical level (75th percentile) of 20.7x
- EV/Sales multiple is 1.7x
The company showed EPS -$0.14 per share vs analyst consensus of +$0.16. At the opening of the session the share price went up +5.6% vs S&P500 +0.4%
------------------------------------------------
#reports #OPTN
[OptiNose](https://eninvs.com/company%5fUS%5fwide.php?name=OPTN) (Drug Manufacturers — Specialty and Generic) reported for 2022 q2:
- Revenue +16.7% YoY (vs +25.0% in previous quarter and historical rate +72.7%)
- EBITDA margin -71.4% increased compared to -105.6% same period last year
- Net Debt increased by $11.0 mln over the past reporting period (3.6% of market cap)
- FCF (LTM) -$0.0 bln (negative), 4.9% of market cap
- EV/Sales multiple is 4.4x
The company showed EPS -$0.23 per share vs analyst consensus of -$0.24. At the opening of the session the share price went down -3.6% vs S&P500 +0.4%
------------------------------------------------
#reports #OEG
[Orbital Energy Group](https://eninvs.com/company%5fUS%5fwide.php?name=OEG) (Utilities — Diversified) reported for 2022 q2:
- Revenue +487.5% YoY (vs +677.8% in previous quarter and historical rate +53.4%)
- Net Debt decreased by $13.0 mln over the past reporting period (19.2% of market cap)
- FCF (LTM) -$0.2 bln (negative), 327.9% of market cap
- EV/Sales multiple is 1.2x
The company showed EPS -$0.32 per share vs analyst consensus of -$0.46
------------------------------------------------
#reports #NOTV
[Inotiv](https://eninvs.com/company%5fUS%5fwide.php?name=NOTV) (Diagnostics and Research) reported for 2022 q2:
- Revenue +652.2% YoY (vs +636.8% in previous quarter and historical rate +85.8%)
- EBITDA margin 2.9% increased compared to -8.7% same period last year
- Net Debt increased by $3.0 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) -$0.3 bln (negative), 54.1% of market cap
- EV/Sales multiple is 2.0x
The company showed EPS +$0.04 per share vs analyst consensus of -$0.02. At the opening of the session the share price went up +24.9% vs S&P500 +0.4%
------------------------------------------------
#reports #MLP
[Maui Land & Pineapple Company](https://eninvs.com/company%5fUS%5fwide.php?name=MLP) (Real Estate Services) reported for 2022 q2:
- Revenue +180.0% YoY (vs 0.0% in previous quarter and historical rate +42.8%)
- EBITDA +450.0% YoY (vs -200.0% in previous quarter)
- EBITDA margin 78.6% increased compared to 40.0% same period last year
- Net Debt decreased by $11.0 mln over the past reporting period (6.0% of market cap)
- FCF (LTM) +$0.0 bln (positive), 6.0% of market cap
- EV/EBITDA multiple is 21.8x compared to historical level (75th percentile) of 98.0x
- EV/Sales multiple is 6.0x
The company showed EPS +$0.54 per share. At the opening of the session the share price went up +3.5% vs S&P500 +0.4%
------------------------------------------------
#reports #LU
[Lufax Holding Ltd](https://eninvs.com/company%5fUS%5fwide.php?name=LU) (Credit Services) reported for 2022 q2:
- Revenue -1.1% YoY (vs +10.8% in previous quarter and historical rate +19.5%)
- Net Income -85.9% YoY (vs -78.2% in previous quarter and historical rate -48.8%)
- Net Income margin 33.7% decreased compared to 235.9% same period last year
- P/E multiple is 3.4x compared to historical level (75th percentile) of 1.7x
- P/S multiple is 1.2x
- Price to book: 0.7x
The company showed EPS +$0.18 per share vs analyst consensus of +$0.23. At the opening of the session the share price went down -0.5% vs S&P500 -0.2%
------------------------------------------------
#reports #KELYB
[Kelly Services](https://eninvs.com/company%5fUS%5fwide.php?name=KELYB) (Staffing and Employment Services) reported for 2022 q2:
- Revenue 0.0% YoY (vs +7.5% in previous quarter and historical rate -2.2%)
- EBITDA -100.0% YoY (vs -382.4% in previous quarter and historical rate -19.9%)
- Net Debt increased by $94.0 mln over the past reporting period (11.0% of market cap)
- FCF (LTM) +$0.2 bln (positive), 24.6% of market cap
- EV/EBITDA multiple is 132.7x compared to historical level (75th percentile) of 15.2x
- EV/Sales multiple is 0.2x
The company showed EPS +$0.62 per share vs analyst consensus of -$0.56. At the opening of the session the share price went up +0.6% vs S&P500 +0.4%
------------------------------------------------
#reports #JRSH
[Jerash (US)](https://eninvs.com/company%5fUS%5fwide.php?name=JRSH) (Apparel Manufacturing) reported for 2022 q2:
- Revenue +10.0% YoY (vs +29.2% in previous quarter and historical rate +24.5%)
- EBITDA 0.0% YoY (vs -50.0% in previous quarter)
- EBITDA margin 9.1% decreased compared to 10.0% same period last year
- Net Debt increased by $4.0 mln over the past reporting period (5.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 9.7% of market cap
- EV/EBITDA multiple is 4.3x compared to historical level (75th percentile) of 6.7x
- EV/Sales multiple is 0.4x
The company showed EPS +$0.14 per share vs analyst consensus of +$0.13
------------------------------------------------
#reports #HSON
[Hudson Global](https://eninvs.com/company%5fUS%5fwide.php?name=HSON) (Staffing and Employment Services) reported for 2022 q2:
- Revenue +27.5% YoY (vs +52.9% in previous quarter and historical rate +41.5%)
- EBITDA margin 7.8% increased compared to 0.0% same period last year
- Net Debt decreased by $9.0 mln over the past reporting period (10.6% of market cap)
- FCF (LTM) +$0.0 bln (positive), 1.2% of market cap
- EV/EBITDA multiple is 5.3x compared to historical level (75th percentile) of 20.0x
- EV/Sales multiple is 0.3x
The company showed EPS +$0.98 per share vs analyst consensus of +$0.96. At the opening of the session the share price went up +10.5% vs S&P500 +0.4%
------------------------------------------------
#reports #HOWL
[Werewolf Therapeutics, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=HOWL) (Biotechnology) reported for 2022 q2:
- Revenue +300.0% YoY (vs -100.0% in previous quarter and historical rate +66.7%)
- Net Debt decreased by $2.0 mln over the past reporting period (1.5% of market cap)
- FCF (LTM) -$0.2 bln (negative), 123.3% of market cap
- EV/Sales multiple is 0.5x
The company showed EPS -$0.53 per share vs analyst consensus of -$0.43
------------------------------------------------
#reports #HBI
[Hanesbrands](https://eninvs.com/company%5fUS%5fwide.php?name=HBI) (Clothes manufacturer) reported for 2022 q2:
- Revenue -13.6% YoY (vs +4.5% in previous quarter and historical rate -1.3%)
- EBITDA -31.0% YoY (vs -9.1% in previous quarter and historical rate +7.3%)
- EBITDA margin 11.0% decreased compared to 13.8% same period last year
- Net Debt increased by $288.0 mln over the past reporting period (7.1% of market cap)
- FCF (LTM) -$0.1 bln (negative), 2.5% of market cap
- EV/EBITDA multiple is 9.4x compared to historical level (75th percentile) of 30.0x
- EV/Sales multiple is 1.2x
The company showed EPS +$0.26 per share vs analyst consensus of +$0.33. At the opening of the session the share price went down -6.9% vs S&P500 +0.4%
------------------------------------------------
#reports #GRIL
[Muscle Maker](https://eninvs.com/company%5fUS%5fwide.php?name=GRIL) (Restaurants) reported for 2022 q2:
- Revenue +200.0% YoY (vs +200.0% in previous quarter and historical rate +62.5%)
- EBITDA margin -33.3% increased compared to -400.0% same period last year
- Net Debt increased by $1.0 mln over the past reporting period (7.9% of market cap)
- EV/Sales multiple is 0.2x
The company showed EPS -$0.06 per share
------------------------------------------------
#reports #GLPG
[Galapagos](https://eninvs.com/company%5fUS%5fwide.php?name=GLPG) (Biotechnology) reported for 2022 q2:
- Revenue -22.8% YoY (vs -6.0% in previous quarter and historical rate +30.6%)
- EBITDA margin 12.0% increased compared to -20.1% same period last year
- Net Debt increased by $290.0 mln over the past reporting period (7.9% of market cap)
- FCF (LTM) -$4.9 bln (negative), 133.6% of market cap
- EV/Sales multiple is 5.2x
The company showed EPS -$0.30 per share vs analyst consensus of -$0.68. At the opening of the session the share price went up +4.7% vs S&P500 -0.9%
------------------------------------------------
#reports #FULC
[Fulcrum Therapeutics](https://eninvs.com/company%5fUS%5fwide.php?name=FULC) (Medicines developer) reported for 2022 q2:
- Revenue -50.0% YoY (vs -40.0% in previous quarter and historical rate +107.7%)
- EBITDA margin -1650.0% decreased compared to -475.0% same period last year
- Net Debt decreased by $8.0 mln over the past reporting period (2.5% of market cap)
- FCF (LTM) -$0.0 bln (negative), 9.8% of market cap
- EV/Sales multiple is 19.4x
The company showed EPS -$0.83 per share vs analyst consensus of -$0.66. At the opening of the session the share price went up +2.6% vs S&P500 +0.4%
------------------------------------------------
#reports #FNCH
[Finch Therapeutics Group, Inc.](https://eninvs.com/company%5fUS%5fwide.php?name=FNCH) (Biotechnology) reported for 2022 q2:
- EBITDA margin -2100.0% decreased compared to -500.0% same period last year
- Net Debt increased by $37.0 mln over the past reporting period (29.9% of market cap)
- FCF (LTM) -$0.1 bln (negative), 84.1% of market cap
- EV/Sales multiple is 5.0x
The company showed EPS -$0.48 per share vs analyst consensus of -$0.46. At the opening of the session the share price went up +14.5% vs S&P500 -0.2%
------------------------------------------------
#reports #EYE
[National Vision](https://eninvs.com/company%5fUS%5fwide.php?name=EYE) (Optics supplier) reported for 2022 q2:
- Revenue -7.1% YoY (vs -1.1% in previous quarter and historical rate +11.9%)
- EBITDA -55.6% YoY (vs -32.4% in previous quarter)
- EBITDA margin 8.6% decreased compared to 18.0% same period last year
- Net Debt increased by $72.0 mln over the past reporting period (2.7% of market cap)
- FCF (LTM) +$0.0 bln (positive), 0.6% of market cap
- EV/EBITDA multiple is 13.1x compared to historical level (75th percentile) of 21.6x
- EV/Sales multiple is 1.7x
The company showed EPS +$0.12 per share vs analyst consensus of +$0.06. At the opening of the session the share price went up +1.9% vs S&P500 +0.4%
------------------------------------------------
#reports #ERF
[Enerplus Corporation](https://eninvs.com/company%5fUS%5fwide.php?name=ERF) (Oil and Gas E and P) reported for 2022 q2:
- Revenue +18.9% YoY (vs +54.4% in previous quarter and historical rate +27.1%)
- EBITDA >1000% YoY (vs +365.4% in previous quarter and historical rate +42.5%)
- EBITDA margin 82.4% increased compared to 7.3% same period last year
- Net Debt decreased by $28.0 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) +$0.7 bln (positive), 20.3% of market cap
- EV/EBITDA multiple is 3.7x compared to historical level (75th percentile) of 6.9x
- EV/Sales multiple is 2.4x
The company showed EPS +$0.77 per share vs analyst consensus of +$0.64. At the opening of the session the share price went down -0.5% vs S&P500 -0.9%
------------------------------------------------
#reports #ENTX
[Entera Bio](https://eninvs.com/company%5fUS%5fwide.php?name=ENTX) (Biotechnology) reported for 2022 q2:
- Net Debt decreased by $17.0 mln over the past reporting period (31.4% of market cap)
- FCF (LTM) +$0.0 bln (positive), 51.7% of market cap
- EV/Sales multiple is 37.2x
Country: UNITED STATES
Sector: Furnishings, Fixtures and Appliances
Quarterly values ($m)
Change (y/y)
FCF / Free Cash Flow ($m)
Net Debt / Cash and Equivalents ($m)
EV / Sales
Potential dynamics
Property | 2022 q1 | 2021 q4 | 2021 q3 | 2021 q2 | 2021 q1 | 2020 q4 | 2020 q3 | 2020 q2 |
---|---|---|---|---|---|---|---|---|
date | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
symbol | WEBR | WEBR | WEBR | WEBR | WEBR | WEBR | WEBR | WEBR |
reportedCurrency | USD | USD | USD | USD | USD | USD | USD | USD |
cik | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M |
fillingDate | 2022-05-16 | 2022-02-14 | 2021-12-14 | 2021-09-16 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
acceptedDate | 2022-05-16 08:48:34 | 2022-02-14 08:41:40 | 2021-12-14 17:04:27 | 2021-09-16 16:26:34 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
calendarYear | 2022.000 | 2022.000 | 2021.000 | 2021.000 | 2021.000 | 2021.000 | 2020.000 | 2020.000 |
period | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 |
revenue | 607M | 283M | 350M | 669M | 654M | 309M | 368M | 561M |
costOfRevenue | 399M | 219M | 245M | 370M | 369M | 174M | 228M | 329M |
grossProfit | 209M | 64M | 106M | 299M | 286M | 135M | 140M | 232M |
grossProfitRatio | 0.343 | 0.226 | 0.302 | 0.447 | 0.437 | 0.436 | 0.380 | 0.413 |
researchAndDevelopmentExpenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
generalAndAdministrativeExpenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
sellingAndMarketingExpenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
sellingGeneralAndAdministrativeExpenses | 166M | 148M | 183M | 258M | 184M | 114M | 140M | 130M |
otherExpenses | 5M | 5M | 5M | 5M | 4M | 3M | 3M | 3M |
operatingExpenses | 171M | 153M | 188M | 263M | 188M | 117M | 143M | 134M |
costAndExpenses | 570M | 372M | 433M | 633M | 556M | 291M | 371M | 463M |
interestIncome | 386 000 | 230 000 | 414 000 | 252 000 | 246 000 | 179 000 | 258 000 | 311 000 |
interestExpense | 17M | 16M | 17M | 18M | 18M | 15M | 8M | 11M |
depreciationAndAmortization | 15M | 14M | 12M | 12M | 11M | 10M | 10M | 10M |
ebitda | 46M | 16M | -31M | 52M | 112M | 29M | 7M | 109M |
ebitdaratio | 0.075 | 0.056 | -0.089 | 0.078 | 0.171 | 0.095 | 0.019 | 0.194 |
operatingIncome | 37M | -89M | -83M | 36M | 98M | 23M | -3M | 98M |
operatingIncomeRatio | 0.062 | -0.315 | -0.236 | 0.054 | 0.150 | 0.074 | -0.008 | 0.175 |
totalOtherIncomeExpensesNet | -22M | -16M | -20M | -14M | -21M | -16M | -8M | -9M |
incomeBeforeTax | 16M | -105M | -102M | 22M | 77M | 6M | -11M | 89M |
incomeBeforeTaxRatio | 0.026 | -0.371 | -0.293 | 0.033 | 0.118 | 0.021 | -0.031 | 0.158 |
incomeTaxExpense | 67M | -30M | -16M | 4M | 15M | 166 000 | 2M | 9M |
netIncome | -54M | 17M | -43M | 18M | 68M | 5M | -14M | 79M |
netIncomeRatio | -0.090 | 0.059 | -0.123 | 0.026 | 0.104 | 0.016 | -0.037 | 0.140 |
eps | -1.020 | 0.310 | -0.130 | 0.235 | 0.910 | 0.097 | -0.272 | 1.569 |
epsdiluted | -1.020 | -0.190 | -0.130 | 0.235 | 0.910 | 0.097 | -0.272 | 1.569 |
weightedAverageShsOut | 53M | 53M | 52M | 75M | 75M | 50M | 50M | 50M |
weightedAverageShsOutDil | 53M | 288M | 52M | 75M | 75M | 50M | 50M | 50M |
link | Link | Link | Link | Link | ||||
finalLink | Link | Link | Link | Link |
Property | 2022 q1 | 2021 q4 | 2021 q3 | 2021 q2 | 2021 q1 | 2020 q3 |
---|---|---|---|---|---|---|
date | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-09-30 |
symbol | WEBR | WEBR | WEBR | WEBR | WEBR | WEBR |
reportedCurrency | USD | USD | USD | USD | USD | USD |
cik | 2M | 2M | 2M | 2M | 2M | 2M |
fillingDate | 2022-05-16 | 2022-02-14 | 2021-12-14 | 2021-09-16 | 2021-03-31 | 2020-09-30 |
acceptedDate | 2022-05-16 08:48:34 | 2022-02-14 08:41:40 | 2021-12-14 17:04:27 | 2021-09-16 16:26:34 | 2021-03-31 | 2020-09-30 |
calendarYear | 2022.000 | 2022.000 | 2021.000 | 2021.000 | 2021.000 | 2020.000 |
period | Q2 | Q1 | Q4 | Q3 | Q2 | Q4 |
cashAndCashEquivalents | 46M | 46M | 108M | 146M | 380M | 124M |
shortTermInvestments | 0 | 0 | 0 | 0 | 0 | 0 |
cashAndShortTermInvestments | 46M | 46M | 108M | 146M | 380M | 124M |
netReceivables | 349M | 156M | 139M | 322M | 484M | 131M |
inventory | 478M | 471M | 333M | 334M | 334M | 233M |
otherCurrentAssets | 76M | 114M | 68M | 44M | 41M | 34M |
totalCurrentAssets | 950M | 787M | 647M | 846M | 1 240M | 522M |
propertyPlantEquipmentNet | 264M | 240M | 230M | 191M | 149M | 157M |
goodwill | 110M | 109M | 111M | 113M | 92M | 31M |
intangibleAssets | 492M | 497M | 502M | 508M | 499M | 396M |
goodwillAndIntangibleAssets | 601M | 606M | 613M | 621M | 591M | 426M |
longTermInvestments | 0 | 0 | 0 | 0 | 0 | 0 |
taxAssets | 0 | 0 | 0 | 0 | 0 | 0 |
otherNonCurrentAssets | 64M | 58M | 61M | 40M | 47M | 34M |
totalNonCurrentAssets | 929M | 904M | 904M | 852M | 787M | 618M |
otherAssets | 0 | 0 | 0 | 0 | 0 | 0 |
totalAssets | 1 878M | 1 691M | 1 551M | 1 698M | 2 026M | 1 139M |
accountPayables | 454M | 376M | 331M | 408M | 384M | 298M |
shortTermDebt | 47M | 174M | 26M | 13M | 13M | 37M |
taxPayables | 27M | 9M | 5M | 8M | 7M | 8M |
deferredRevenue | 0 | 0 | 0 | 0 | 0 | 0 |
otherCurrentLiabilities | 174M | 145M | 142M | 188M | 182M | 142M |
totalCurrentLiabilities | 676M | 695M | 499M | 609M | 579M | 477M |
longTermDebt | 1 318M | 1 077M | 1 079M | 1 304M | 1 283M | 653M |
deferredRevenueNonCurrent | 0 | 0 | 0 | 0 | 0 | 0 |
deferredTaxLiabilitiesNonCurrent | 0 | 0 | 0 | 0 | 0 | 0 |
otherNonCurrentLiabilities | 79M | 89M | 95M | 187M | 138M | 53M |
totalNonCurrentLiabilities | 1 397M | 1 165M | 1 173M | 1 491M | 1 421M | 706M |
otherLiabilities | 0 | 0 | 0 | 0 | 0 | 0 |
capitalLeaseObligations | 100M | 95M | 107M | 96M | 73M | 77M |
totalLiabilities | 2 072M | 1 860M | 1 672M | 2 100M | 1 999M | 1 183M |
preferredStock | 0 | 0 | 0 | 0 | 0 | 0 |
commonStock | 55 000 | 55 000 | 55 000 | -742 000 | -538 000 | -1M |
retainedEarnings | -50M | 7M | -8M | -355M | 70M | 26M |
accumulatedOtherComprehensiveIncomeLoss | -6M | -9M | -9M | -46M | -43M | -69M |
othertotalStockholdersEquity | 15M | 12M | 6M | 0 | 0 | 0 |
totalStockholdersEquity | -40M | 10M | -11M | -402M | 27M | -44M |
totalLiabilitiesAndStockholdersEquity | 2 032M | 1 870M | 1 662M | 1 698M | 2 026M | 1 139M |
minorityInterest | -154M | -179M | -111M | 0 | 0 | 0 |
totalEquity | -194M | -169M | -121M | -402M | 27M | -44M |
totalLiabilitiesAndTotalEquity | 1 878M | 1 691M | 1 551M | 1 698M | 2 026M | 1 139M |
totalInvestments | 0 | 0 | 0 | 0 | 0 | 0 |
totalDebt | 1 365M | 1 251M | 1 105M | 1 317M | 1 296M | 689M |
netDebt | 1 319M | 1 205M | 997M | 1 171M | 916M | 566M |
link | Link | Link | Link | Link | ||
finalLink | Link | Link | Link | Link |
Property | 2022 q1 | 2021 q4 | 2021 q3 | 2021 q2 | 2021 q1 | 2020 q4 | 2020 q3 | 2020 q2 |
---|---|---|---|---|---|---|---|---|
date | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
symbol | WEBR | WEBR | WEBR | WEBR | WEBR | WEBR | WEBR | WEBR |
reportedCurrency | USD | USD | USD | USD | USD | USD | USD | USD |
cik | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M |
fillingDate | 2022-05-16 | 2022-02-14 | 2021-12-14 | 2021-09-16 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
acceptedDate | 2022-05-16 08:48:34 | 2022-02-14 08:41:40 | 2021-12-14 17:04:27 | 2021-09-16 16:26:34 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 |
calendarYear | 2022.000 | 2022.000 | 2021.000 | 2021.000 | 2021.000 | 2021.000 | 2020.000 | 2020.000 |
period | Q2 | Q1 | Q4 | Q3 | Q2 | Q1 | Q4 | Q3 |
netIncome | -51M | 17M | -43M | 18M | 68M | 5M | -14M | 79M |
depreciationAndAmortization | 15M | 14M | 12M | 12M | 11M | 10M | 10M | 10M |
deferredIncomeTax | 3M | 340 000 | 0 | 0 | 0 | -2M | 0 | 0 |
stockBasedCompensation | 22M | 26M | 42M | 58M | 27M | 3M | 0 | 0 |
changeInWorkingCapital | -45M | -154M | 29M | 197M | -158M | -180M | 183M | 241M |
accountsReceivables | -197M | -18M | 179M | 167M | -312M | -41M | 177M | 98M |
inventory | -13M | -140M | -3M | 3M | -23M | -76M | -17M | 97M |
accountsPayables | 85M | 52M | -93M | 22M | 118M | -35M | 44M | -25M |
otherWorkingCapital | 2M | 6M | 25M | 2M | -3M | -11M | 314 000 | -7M |
otherNonCashItems | 1M | -90M | -60M | 4M | -2M | 3M | 4M | 3M |
netCashProvidedByOperatingActivities | -55M | -188M | -20M | 289M | -53M | -161M | 184M | 333M |
investmentsInPropertyPlantAndEquipment | -36M | -26M | -23M | -23M | -12M | -5M | -7M | -4M |
acquisitionsNet | 0 | 0 | 0 | -26M | 0 | 0 | 0 | 0 |
purchasesOfInvestments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
salesMaturitiesOfInvestments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
otherInvestingActivites | 3000.000 | 10000.000 | 1000.000 | 0 | -100M | 12M | 642 000 | 7M |
netCashUsedForInvestingActivites | -36M | -26M | -23M | -49M | -112M | 7M | -6M | 2M |
debtRepayment | -353M | -45M | -223M | -220M | -3M | -616M | -255M | -302M |
commonStockIssued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
commonStockRepurchased | 0 | 0 | -36M | 0 | 0 | 0 | 0 | 0 |
dividendsPaid | -17M | -12M | 114 000 | -285M | -1M | -29M | -7M | -8M |
otherFinancingActivites | 458M | 210M | 266M | 37M | -1M | 1 223M | 107M | -1M |
netCashUsedProvidedByFinancingActivities | 88M | 153M | 7M | -469M | -6M | 577M | -155M | -311M |
effectOfForexChangesOnCash | 3M | -895 000 | -2M | -4M | 5M | -381 000 | 2M | 3M |
netChangeInCash | 182 000 | -61M | -39M | -233M | -166M | 422M | 25M | 27M |
cashAtEndOfPeriod | 46M | 46M | 108M | 146M | 380M | 546M | 124M | 99M |
cashAtBeginningOfPeriod | 46M | 108M | 146M | 380M | 546M | 124M | 99M | 72M |
operatingCashFlow | -55M | -188M | -20M | 289M | -53M | -161M | 184M | 333M |
capitalExpenditure | -36M | -26M | -23M | -23M | -12M | -5M | -7M | -4M |
freeCashFlow | -91M | -214M | -43M | 266M | -66M | -166M | 177M | 329M |
link | Link | Link | Link | Link | ||||
finalLink | Link | Link | Link | Link |
Q | Earning call transcript | Income Statement | Balance Sheet Statement | Cash Flow Statement |
---|---|---|---|---|
2022 q2 | ||||
2022 q1 | 2022-05-16 (fiscal 2022 q2) |
2022-05-16 | 2022-05-16 | 2022-03-31 |
2021 q4 | 2022-02-14 (fiscal 2022 q1) |
2022-02-14 | 2022-02-14 | 2022-02-14 |
2021 q3 | 2021-12-08 (fiscal 2021 q4) |
2021-12-14 | 2021-12-14 | 2021-12-14 |
2021 q2 | 2021-09-15 (fiscal 2021 q3) |
2021-09-16 | 2021-09-16 | 2021-09-16 |
2021 q1 | 2021-03-31 | 2021-03-31 | 2021-03-31 | |
2020 q4 | 2020-12-31 | 2020-12-31 | ||
2020 q3 | 2020-09-30 | 2020-09-30 | 2020-09-30 | |
2020 q2 | 2020-06-30 | 2020-06-30 | ||
2020 q1 |